SANUWAVE Q1 FY26 operating loss swings to $1.1 million; revenue rises 3.1% to $9.6 million

• SANUWAVE Health posted Q1 FY2026 revenue of $9.6 million, up 3.1%, while operating results swung to a GAAP operating loss of $1.1 million.
• Net loss narrowed to $1.4 million, versus a prior-year period hit that included a $4.9 million non-cash loss tied to derivative liabilities.
• Gross margin fell 1.7 percentage points to 77.3% on lower pricing for Ultramist systems and applicators tied to wholesale sales to resellers.
• Ultramist consumables revenue rose 15% to $6.7 million, while 97 Ultramist systems were sold; management said recovery appeared to begin in February as utilization improved.
• Forecasts Q2 revenue of $11.1 million to $11.6 million, reiterating full-year revenue guidance of $51 million to $55 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SANUWAVE Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-034149), on May 12, 2026, and is solely responsible for the information contained therein.